Aptamers Market, 2012 to 2023
Aptamers market is growing at a significant CAGR owing to rise in the investment in biotechnology and pharmaceutical companies for R&D activities, technological developments, an increase in the therapeutic application anticipated to fuel the aptamers market over the forecast period. Furthermore, increase in the using of aptamers in drug discovery, entry of private organizations in research and development space, and advantages of aptamers over other therapeutics expected to drive the aptamers market. However, stringent regulatory policies and ethical issues in aptamers usage, dearth of aptamers in the market in the undeveloped regions, and lack of awareness about the aptamers usage expected to dampen the growth of aptamers market over the forecast period.
Global Aptamers Market
Aptamers are the single-stranded peptide or oligonucleotide molecules that bind to the protein, nucleic acid molecules or target lipid with the high specificity. Aptamers are used in pharmaceutical studies, laboratory diagnosis, drug discovery, molecular recognition, and treatment of certain diseases. In addition, aptamers are also used in the production of cost-effective and improved medicines, the advantages of aptamers over protein therapeutics include in terms of synthetic accessibility, modification, and size. Aptamers are commonly used in the treatment of AIDS owing to faster development than the antibodies which lead to curing of diseases very faster.
Global aptamers market is segmented on the basis of aptamers type, application, and end user
Based on the aptamers type, Aptamers market is segmented into the following:
Nucleic acid aptamers
RNA-based
XNA-based
DNA-based
Peptide aptamers
Based on the application, This market is segmented into the following
Research & Development
Therapeutic development
Diagnostics
Based on the end user, This market is segmented into the following:
Pharmaceutical companies
Biopharmaceutical companies
Research and academic institutes
Others
Nowadays, Aptamers market is the growing stage with an increase in R&D activities by the various biopharmaceutical companies and research institutes. Technological advancements and drug innovations are expected to fuel the aptamers market. For instance, in 2014, MIT scientists created DNA-based drug targeting system comprising of aptamers and ultraviolet light which leads to binding of aptamers with high specificity. Acquisitions and mergers, collaborations, newer technologies launches, fundraising for aptamers development and patent approvals are some key strategies adopted by the companies to increase their share in the global aptamers market. For instance, in February 2012, Valent pharmaceutical acquired Eyetech and enters into the aptamers market with the marketing of Macugen anti-VEGF aptamers in U.S. Moreover, in February 2016, researchers from Institute of Bioengineering and Nanotechnology (Singapore) have developed more efficient DNA technology for detection and treatment of cancer and infectious diseases.
Geographically, Aptamers market is segmented into following regions, Viz. Europe, Latin America, North America, Asia Pacific, and the Middle East and Africa. North America is expected to hold a dominant share in aptamers market owing to technological advancements, a rise in collaboration of biopharmaceutical companies for R&D activities, and favourable government regulations for clinical trials. Europe has a significant growth in aptamers market owing to the adoption of developed aptamer technologies, increase in the prevalence of chronic diseases, an increase in the preference for aptamer-based treatment in Europe countries is the key factors expected to drive the aptamers market growth. Asia Pacific has shown lucrative growth over the forecast period owing to increase in the incidence and prevalence of chronic diseases, rise in demand for cost-effective treatment, increase in healthcare expenditure, and adoption of novel technologies majorly in Japan and China are the factors `expected to boost the aptamers market in the region.
Some of the players in Aptamers market are NeoVentures Biotechnology, Inc. (Canada), Aptagen, LLC (U.S.), Aptamer Solutions Ltd. (U.K.), SomaLogic, Inc. (U.S.), AM Biotechnologies, LLC (U.S.), TriLink BioTechnologies, Inc. (U.S.), Vivonics, Inc. (U.S.), and Apta Targets (Spain) to name a few.
In May 2017, AptaTargets raised € 2.7 Mn funding from Caixa Capital Risc for the development of clinical trials for ApTOLL, a drug used in the treatment of acute ischemic stroke
Global Aptamers Market
Aptamers are the single-stranded peptide or oligonucleotide molecules that bind to the protein, nucleic acid molecules or target lipid with the high specificity. Aptamers are used in pharmaceutical studies, laboratory diagnosis, drug discovery, molecular recognition, and treatment of certain diseases. In addition, aptamers are also used in the production of cost-effective and improved medicines, the advantages of aptamers over protein therapeutics include in terms of synthetic accessibility, modification, and size. Aptamers are commonly used in the treatment of AIDS owing to faster development than the antibodies which lead to curing of diseases very faster.
Global aptamers market is segmented on the basis of aptamers type, application, and end user
Based on the aptamers type, Aptamers market is segmented into the following:
Nucleic acid aptamers
RNA-based
XNA-based
DNA-based
Peptide aptamers
Based on the application, This market is segmented into the following
Research & Development
Therapeutic development
Diagnostics
Based on the end user, This market is segmented into the following:
Pharmaceutical companies
Biopharmaceutical companies
Research and academic institutes
Others
Nowadays, Aptamers market is the growing stage with an increase in R&D activities by the various biopharmaceutical companies and research institutes. Technological advancements and drug innovations are expected to fuel the aptamers market. For instance, in 2014, MIT scientists created DNA-based drug targeting system comprising of aptamers and ultraviolet light which leads to binding of aptamers with high specificity. Acquisitions and mergers, collaborations, newer technologies launches, fundraising for aptamers development and patent approvals are some key strategies adopted by the companies to increase their share in the global aptamers market. For instance, in February 2012, Valent pharmaceutical acquired Eyetech and enters into the aptamers market with the marketing of Macugen anti-VEGF aptamers in U.S. Moreover, in February 2016, researchers from Institute of Bioengineering and Nanotechnology (Singapore) have developed more efficient DNA technology for detection and treatment of cancer and infectious diseases.
Geographically, Aptamers market is segmented into following regions, Viz. Europe, Latin America, North America, Asia Pacific, and the Middle East and Africa. North America is expected to hold a dominant share in aptamers market owing to technological advancements, a rise in collaboration of biopharmaceutical companies for R&D activities, and favourable government regulations for clinical trials. Europe has a significant growth in aptamers market owing to the adoption of developed aptamer technologies, increase in the prevalence of chronic diseases, an increase in the preference for aptamer-based treatment in Europe countries is the key factors expected to drive the aptamers market growth. Asia Pacific has shown lucrative growth over the forecast period owing to increase in the incidence and prevalence of chronic diseases, rise in demand for cost-effective treatment, increase in healthcare expenditure, and adoption of novel technologies majorly in Japan and China are the factors `expected to boost the aptamers market in the region.
Some of the players in Aptamers market are NeoVentures Biotechnology, Inc. (Canada), Aptagen, LLC (U.S.), Aptamer Solutions Ltd. (U.K.), SomaLogic, Inc. (U.S.), AM Biotechnologies, LLC (U.S.), TriLink BioTechnologies, Inc. (U.S.), Vivonics, Inc. (U.S.), and Apta Targets (Spain) to name a few.
In May 2017, AptaTargets raised € 2.7 Mn funding from Caixa Capital Risc for the development of clinical trials for ApTOLL, a drug used in the treatment of acute ischemic stroke
1. EXECUTIVE SUMMARY
2. GLOBAL APTAMERS MARKET INTRODUCTION
2.1. Global Aptamers Market – Taxonomy
2.2. Global Aptamers Market –Definitions
2.2.1. Aptamer Type
2.2.2. Application
2.2.3. End-User
3. GLOBAL APTAMERS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Aptamers Market Dynamics – Factors Impact Analysis
3.6. Global Aptamers Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL APTAMERS MARKET, BY APTAMER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Nucleic acid aptamers
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. RNA-based
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XNA-based
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. DNA-based
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Peptide aptamers
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL APTAMERS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Research & Development
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Therapeutic development
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Diagnostics
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL APTAMERS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Pharmaceutical companies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Biopharmaceutical companies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research and academic institutes
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL APTAMERS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Region, 2017 – 2023
9. NORTH AMERICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Nucleic acid aptamers
9.1.2. RNA-based
9.1.3. XNA-based
9.1.4. DNA-based
9.1.5. Peptide aptamers
9.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Research & Development
9.2.2. Therapeutic development
9.2.3. Diagnostics
9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Pharmaceutical companies
9.3.2. Biopharmaceutical companies
9.3.3. Research and academic institutes
9.3.4. Others
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Aptamers Market - Opportunity Analysis Index, By Aptamer Type,By Application, By End-User, and Country, 2017 – 2023
9.6. North America Aptamers Market Dynamics – Trends
10. EUROPE APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Nucleic acid aptamers
10.1.2. RNA-based
10.1.3. XNA-based
10.1.4. DNA-based
10.1.5. Peptide aptamers
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Research & Development
10.2.2. Therapeutic development
10.2.3. Diagnostics
10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Pharmaceutical companies
10.3.2. Biopharmaceutical companies
10.3.3. Research and academic institutes
10.3.4. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User,and Country, 2017 – 2023
10.6. Europe Aptamers Market Dynamics – Trends
11. ASIA-PACIFIC APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Nucleic acid aptamers
11.1.2. RNA-based
11.1.3. XNA-based
11.1.4. DNA-based
11.1.5. Peptide aptamers
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Research & Development
11.2.2. Therapeutic development
11.2.3. Diagnostics
11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Pharmaceutical companies
11.3.2. Biopharmaceutical companies
11.3.3. Research and academic institutes
11.3.4. Others
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Country, 2017 – 2023
11.6. Europe Aptamers Market Dynamics – Trends
12. LATIN AMERICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Nucleic acid aptamers
12.1.2. RNA-based
12.1.3. XNA-based
12.1.4. DNA-based
12.1.5. Peptide aptamers
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Research & Development
12.2.2. Therapeutic development
12.2.3. Diagnostics
12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Pharmaceutical companies
12.3.2. Biopharmaceutical companies
12.3.3. Research and academic institutes
12.3.4. Others
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Country, 2017 – 2023
12.6. Latin America Aptamers Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Nucleic acid aptamers
13.1.2. RNA-based
13.1.3. XNA-based
13.1.4. DNA-based
13.1.5. Peptide aptamers
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Research & Development
13.2.2. Therapeutic development
13.2.3. Diagnostics
13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Pharmaceutical companies
13.3.2. Biopharmaceutical companies
13.3.3. Research and academic institutes
13.3.4. Others
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User,and Country, 2017 – 2023
13.6. MEA Aptamers Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. NeoVentures Biotechnology, Inc. (Canada)
14.2.2. Aptagen, LLC (U.S.)
14.2.3. Aptamer Solutions Ltd. (U.K.)
14.2.4. SomaLogic, Inc. (U.S.)
14.2.5. AM Biotechnologies, LLC (U.S.)
14.2.6. TriLink BioTechnologies, Inc. (U.S.)
14.2.7. Vivonics, Inc. (U.S.)
14.2.8. Apta Targets (Spain)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL APTAMERS MARKET INTRODUCTION
2.1. Global Aptamers Market – Taxonomy
2.2. Global Aptamers Market –Definitions
2.2.1. Aptamer Type
2.2.2. Application
2.2.3. End-User
3. GLOBAL APTAMERS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Aptamers Market Dynamics – Factors Impact Analysis
3.6. Global Aptamers Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL APTAMERS MARKET, BY APTAMER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Nucleic acid aptamers
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. RNA-based
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XNA-based
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. DNA-based
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Peptide aptamers
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL APTAMERS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Research & Development
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Therapeutic development
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Diagnostics
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL APTAMERS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Pharmaceutical companies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Biopharmaceutical companies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research and academic institutes
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL APTAMERS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Region, 2017 – 2023
9. NORTH AMERICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Nucleic acid aptamers
9.1.2. RNA-based
9.1.3. XNA-based
9.1.4. DNA-based
9.1.5. Peptide aptamers
9.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Research & Development
9.2.2. Therapeutic development
9.2.3. Diagnostics
9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Pharmaceutical companies
9.3.2. Biopharmaceutical companies
9.3.3. Research and academic institutes
9.3.4. Others
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Aptamers Market - Opportunity Analysis Index, By Aptamer Type,By Application, By End-User, and Country, 2017 – 2023
9.6. North America Aptamers Market Dynamics – Trends
10. EUROPE APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Nucleic acid aptamers
10.1.2. RNA-based
10.1.3. XNA-based
10.1.4. DNA-based
10.1.5. Peptide aptamers
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Research & Development
10.2.2. Therapeutic development
10.2.3. Diagnostics
10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Pharmaceutical companies
10.3.2. Biopharmaceutical companies
10.3.3. Research and academic institutes
10.3.4. Others
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User,and Country, 2017 – 2023
10.6. Europe Aptamers Market Dynamics – Trends
11. ASIA-PACIFIC APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Nucleic acid aptamers
11.1.2. RNA-based
11.1.3. XNA-based
11.1.4. DNA-based
11.1.5. Peptide aptamers
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Research & Development
11.2.2. Therapeutic development
11.2.3. Diagnostics
11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Pharmaceutical companies
11.3.2. Biopharmaceutical companies
11.3.3. Research and academic institutes
11.3.4. Others
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Country, 2017 – 2023
11.6. Europe Aptamers Market Dynamics – Trends
12. LATIN AMERICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Nucleic acid aptamers
12.1.2. RNA-based
12.1.3. XNA-based
12.1.4. DNA-based
12.1.5. Peptide aptamers
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Research & Development
12.2.2. Therapeutic development
12.2.3. Diagnostics
12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Pharmaceutical companies
12.3.2. Biopharmaceutical companies
12.3.3. Research and academic institutes
12.3.4. Others
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User, and Country, 2017 – 2023
12.6. Latin America Aptamers Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA APTAMERS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Aptamer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Nucleic acid aptamers
13.1.2. RNA-based
13.1.3. XNA-based
13.1.4. DNA-based
13.1.5. Peptide aptamers
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Research & Development
13.2.2. Therapeutic development
13.2.3. Diagnostics
13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Pharmaceutical companies
13.3.2. Biopharmaceutical companies
13.3.3. Research and academic institutes
13.3.4. Others
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Aptamers Market - Opportunity Analysis Index, By Aptamer Type, By Application, By End-User,and Country, 2017 – 2023
13.6. MEA Aptamers Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. NeoVentures Biotechnology, Inc. (Canada)
14.2.2. Aptagen, LLC (U.S.)
14.2.3. Aptamer Solutions Ltd. (U.K.)
14.2.4. SomaLogic, Inc. (U.S.)
14.2.5. AM Biotechnologies, LLC (U.S.)
14.2.6. TriLink BioTechnologies, Inc. (U.S.)
14.2.7. Vivonics, Inc. (U.S.)
14.2.8. Apta Targets (Spain)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
